Research And Development
Biotechnology
Biopharmaceutical

BioCryst

$7.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-3.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioCryst and other stocks, options, ETFs, and crypto commission-free!

About

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. Read More The company was founded in 1986 and is headquartered in Durham, NC.

Employees
100
Headquarters
Durham, North Carolina
Founded
1986
Market Cap
868.40M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
720.93K
High Today
$7.95
Low Today
$7.57
Open Price
$7.87
Volume
221.53K
52 Week High
$9.95
52 Week Low
$4.53

Collections

Research And Development
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Technology
US
North America

News

Seeking AlphaMar 12

BioCryst Pharmaceuticals (BCRX) Presents At Barclays Global Healthcare Conference - Slideshow

The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event. 1 22 Click to enlarge Notes:...

69
Yahoo FinanceMar 8

Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT

Q4 2018 BioCryst Pharmaceuticals Inc Earnings Call BIRMINGHAM Mar 8, 2019 (Thomson StreetEvents) -- Edited Transcript of BioCryst Pharmaceuticals Inc earnings conference call or presentation Monday, March 4, 2019 at 1:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Jon P. Stonehouse BioCryst Pharmaceuticals, Inc. - CEO, Presi...

21
Seeking AlphaMar 4

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2018 Results - Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2018 Results Earnings Conference Call March 4, 2019 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Dr. Bill Sheridan - Chief Medical Officer and Senior Vice President Lynne Powell - Senior Vice President & Chief Commercial Officer Tom Staab - Senior Vice President, Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Owen Drinkwater - RBC Capital Markets Tyler Van Bu...

25

Earnings

-$0.28
-$0.24
-$0.19
-$0.15
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.